Ironwood Pharmaceuticals Inc Revenue Growth Rates (IRWD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ironwood Pharmaceuticals inc   (NASDAQ: IRWD)
 

IRWD's Revenue Growth by Quarter and Year

Ironwood Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IRWD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 113.04
1st Quarter March 106.51
FY 219.55

IRWDs Annual Revenue
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 296.15 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 351.41 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 442.74 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 410.60 millions
Ironwood Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 413.75 millions




IRWD Revenue second quarter 2026 Y/Y Growth Comment
Ironwood Pharmaceuticals inc achieved in the second quarter 2026, above Company average Revenue growth of 32.61% year on year, to $ 113.04 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 127 other companies have achieved higher Revenue growth. While Ironwood Pharmaceuticals Inc ' s Revenue rise of 32.61% ranks overall at the positon no. 2841 in the second quarter 2026.


IRWD Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -47.31 % -22.97 % 9.65 %
3rd Quarter September - 33.27 % -19.47 % 4.69 %
2nd Quarter June 32.61 % -9.7 % -12.09 % 10.44 %
1st Quarter March 158.9 % -45.06 % -28.04 % 6.7 %
FY   - -15.73 % -20.62 % -

Financial Statements
Ironwood Pharmaceuticals Inc 's second quarter 2026 Revenue $ 113.04 millions IRWD's Income Statement
Ironwood Pharmaceuticals Inc 's second quarter 2025 Revenue $ 85.24 millions Quarterly IRWD's Income Statement


IRWD Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -60.91 % -1.14 % 3.35 %
3rd Quarter September - 43.2 % -2.98 % 5.92 %
2nd Quarter June 6.13 % 107.19 % 26.07 % 3.19 %
1st Quarter March 123.24 % -54.57 % -36.3 % -2.93 %
FY (Year on Year)   - -15.73 % -20.62 % -


Back to IRWD Growth rate Comparisons >> Back to IRWD Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #128
Healthcare Sector #406
Overall #2841

Revenue Y/Y Growth Statistics
High Average Low
255.54 % 32.37 % -84.77 %
(Jun 30 2015)   (Dec 31 2013)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #128
Healthcare Sector #406
Overall #2841
Revenue Y/Y Growth Statistics
High Average Low
255.54 % 32.37 % -84.77 %
(Jun 30 2015)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ironwood Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
560.18 % 23.72 % -87.94 %
(Sep 30 2012)  


IRWD's II. Quarter Q/Q Revenue Comment
Ironwood Pharmaceuticals inc achieved in the II. Quarter 2026 below company average Revenue increase of 6.13% quarter on quarter, to $ 113.04 millions.

Within Major Pharmaceutical Preparations industry 65 other companies have achieved higher Revenue quarter on quarter growth. While Ironwood Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1047.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #157
Overall #1047
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #157
Overall #1047
Revenue Q/Q Growth Statistics
High Average Low
560.18 % 23.72 % -87.94 %
(Sep 30 2012)  


IRWD's II. Quarter Q/Q Revenue Comment
Ironwood Pharmaceuticals inc achieved in the II. Quarter 2026 below company average Revenue increase of 6.13% quarter on quarter, to $ 113.04 millions.

Within Major Pharmaceutical Preparations industry 65 other companies have achieved higher Revenue quarter on quarter growth. While Ironwood Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 1047.


Ironwood Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 389.32 $ 361.51 $ 296.15 $ 338.99 $ 308.52
Y / Y Revenue Growth (TTM) 26.19 % 13.8 % -15.72 % -10.42 % -22.98 %
Year on Year Revenue Growth Overall Ranking # 3454 # 3218 # 2349 # 2623 # 2478
Seqeuential Revenue Change (TTM) 7.69 % 22.07 % -12.64 % 9.88 % -2.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 2888 # 2962 # 2155 # 2392 # 2271


Cumulative Revenue growth Comment
Although Ironwood Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 32.37% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 26.19% year on year, from 13.8% in Mar 31 2026.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3454.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 460
Overall # 3454

Revenue TTM Y/Y Growth Statistics
High Average Low
255.54 %
 32.37 %
-84.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 128
Sector # 406
S&P 500 # 2888
Cumulative Revenue growth Comment
Although Ironwood Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 32.37% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 26.19% year on year, from 13.8% in Mar 31 2026.

In the Healthcare sector 459 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3218 to 3454.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 128
Healthcare Sector # 460
Overall # 3454

Revenue TTM Y/Y Growth Statistics
High Average Low
255.54 %
32.37 %
-84.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 128
Sector # 406
S&P 500 # 2888




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IRWD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions


About Ironwood Pharmaceuticals Inc Revenue Growth Rates (IRWD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ironwood Pharmaceuticals Inc (CIK 1446847).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-091987
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ironwood Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.